AbbVie’s $100bn deal aligns drug pricing with domestic manufacturing goals
AbbVie’s latest agreement with the Trump administration underscores a major shift in US drug pricing policy, one in which domestic manufacturing is no longer a peripheral concern but it is built into the deal itself.
